CN1165305C - 尼莫地平冻干组合物 - Google Patents
尼莫地平冻干组合物 Download PDFInfo
- Publication number
- CN1165305C CN1165305C CNB021556458A CN02155645A CN1165305C CN 1165305 C CN1165305 C CN 1165305C CN B021556458 A CNB021556458 A CN B021556458A CN 02155645 A CN02155645 A CN 02155645A CN 1165305 C CN1165305 C CN 1165305C
- Authority
- CN
- China
- Prior art keywords
- nimodipine
- compositions
- phospholipid
- surfactant
- tween
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 title claims description 48
- 229960000715 nimodipine Drugs 0.000 title claims description 48
- 239000007924 injection Substances 0.000 claims abstract description 15
- 238000002347 injection Methods 0.000 claims abstract description 15
- 239000004094 surface-active agent Substances 0.000 claims abstract description 12
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 10
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000004108 freeze drying Methods 0.000 claims description 17
- 150000003904 phospholipids Chemical group 0.000 claims description 16
- -1 polyoxyethylene Polymers 0.000 claims description 12
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 241001597008 Nomeidae Species 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 229960000502 poloxamer Drugs 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- JCABVIFDXFFRMT-DIPNUNPCSA-N [(2r)-1-[ethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] octadec-9-enoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC)OC(=O)CCCCCCCC=CCCCCCCCC JCABVIFDXFFRMT-DIPNUNPCSA-N 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000008347 soybean phospholipid Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 5
- 239000002552 dosage form Substances 0.000 abstract description 3
- 230000002349 favourable effect Effects 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000000843 powder Substances 0.000 description 15
- 239000007788 liquid Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229960004756 ethanol Drugs 0.000 description 5
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000001246 colloidal dispersion Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229930193551 sterin Natural products 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- FGDQGIKMWOAFIK-UHFFFAOYSA-N acetonitrile;phosphoric acid Chemical compound CC#N.OP(O)(O)=O FGDQGIKMWOAFIK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Abstract
本发明提供了尼莫地平冻干组合物及其制备方法。本发明组合物中还含有磷脂、环糊精及其衍生物或表面活性剂，该制品具有良好的溶解性和稳定性，适于用作安全、稳定的注射剂型。
Description
技术领域
本发明涉及包含水不溶性尼莫地平的药物组合物，具体地说，是涉及含有尼莫地平的冷冻干燥药物组合物及其制备方法。
背景技术
尼莫地平(分子式为C21H26N2O2，分子量为418.45)是1，4-二氢吡啶类钙通道拮抗剂，能选择性作用于脑血管，具有扩张脑动脉、增加脑部血流量的作用，主要用于治疗缺血型脑血管疾病，预防和治疗蛛网膜下腔出血后脑血管痉挛、突发性耳聋、高血压及偏头痛等。
目前，国内外上市的尼莫地平剂型很多，其中口服剂型包括普通片剂、缓释片剂、胶囊剂、软胶囊；注射剂包括小水针和大输液。由于尼莫地平固体制剂在胃肠液中溶解度很小，肝首过效应明显，一直存在着生物利用度低的缺点。其注射剂型比口服制剂起效更快、效果更好，所以注射剂型在临床上的应用更为广泛。
然而，尼莫地平难溶于水的特性极大地限制了其临床应用。例如，市售的输液中通常需要加入助溶剂(例如聚维酮等)，与尼莫地平形成络合物，来增加尼莫地平的溶解度。但是，这些措施的效力是有限的。通常，输液中含有20％(v/v)以上的乙醇作为溶剂，而小水针中的乙醇量则更大。如此大量的乙醇，在使用中对病人的刺激性和副作用较大(例如，疼痛、脉管炎等)，并且与乙醇不相容的药物不能一并加入到同一个输液瓶中，使用极其不便。
另外，尼莫地平对光非常不稳定(在溶液状态下尤其明显)，市售注射液大多采用避光的包装材料(例如，采用棕色安瓶、瓶子外加套防光照的泡沫层)，这不但增加成本，而且使用也不方便。通常，溶液中需要添加抗氧剂(例如亚硫酸氢钠)以增加溶液的稳定性。有研究表明，含有尼莫地平的常规小水针在自然光照条件下放置约6分钟，其含量即下降约10％，说明小水针对光照极其不稳定。
因此，本领域非常需要将尼莫地平制成具有良好溶解性和稳定性的制剂。
发明内容
我们对制药工艺进行了深入的研究，最终发现采用冷冻干燥工艺可有效地解决上述问题，在此基础上的进一步研究即完成了本发明。
研究发现，常规冻干剂型虽可解决制剂的稳定性问题，但是产品中尼莫地平的溶解性能并未得到明显改善，还需加入其他附加剂，由此产生的不良反应较多。本发明人惊奇地发现，向尼莫地平中加入磷脂、β-环糊精及其衍生物或表面活性剂，经冷冻干燥可制得稳定的冻干制品，在使用时加入药用水性稀释剂，即可迅速重建成胶体分散体或溶液。另外，本发明组合物中不含乙醇等溶剂，因此避免了刺激性反应。
本发明的一个目的是提供含有磷脂的尼莫地平冻干组合物。磷脂具有两亲性，使其特别适于配制本发明水不溶性尼莫地平，这对于改善尼莫地平的溶解性和体内作用时间是非常有益的。采用本领域常规方法，例如薄膜法、反相蒸发法或冷冻干燥法，并对磷脂的用量加以调整，可制得含有尼莫地平的脂质体或脂质复合物，优选为脂质复合物，然后再经冷冻干燥制成稳定的粉末，所得冻干制品经适量药用水性稀释剂后可迅速重建成胶体分散体。本发明所用磷脂并不局限于特定种类的磷脂，所述磷脂应适于冻干处理并且与尼莫地平相容，可以是植物或动物来源的磷脂，包括天然或合成磷脂。示例性磷脂包括但不限于：卵磷脂、大豆磷脂、脑磷脂、磷脂酸、二棕榈酸磷脂酰胆碱、氢磷脂酰乙醇氨、磷脂酰丝氨酸及其混合物。另外，加入固醇对制剂是有利的，所述固醇选自胆固醇、二氨胆固醇、大豆甾酰糖苷、大豆甾醇、麦角固醇及其混合物。有利地，尼莫地平与磷脂的重量比例约1∶1-1∶100，优选为1∶5-1∶80。
本发明的另一个目的是提供含有环糊精的尼莫地平冻干组合物。难溶性药物尼莫地平经环糊精包合物后，可显著改善其物化特性，例如：将药物粉末化后可提高其稳定性，增加其溶解性。优选地，所述环糊精及其衍生物选自β-环糊精、2-羟丙基-β-环糊精、3-羟丙基-β-环糊精、羟乙基-β-环糊精以及它们的混合物，优选为2-羟丙基-β-环糊精。其中尼莫地平与环糊精的摩尔比约1∶1-1∶20，优选为1∶5-1∶10。其中的包合温度、分散力大小和搅拌速度等条件，可采用常规方法来设计选择。
本发明的另一个目的是提供含有表面活性剂的尼莫地平冻干组合物。如上所述，含有尼莫地平的冻干制剂经药用稀释剂稀释后，时常会出现混浊或结晶现象，这给临床应用带来了一定的风险。本发明通过使用表面活性剂(例如吐温)增溶尼莫地平，促进了其快速溶解，同时又避免了的刺激性溶剂使用。研究表明，下列表面活性剂对尼莫地平具有较好的增溶效果：吐温-20、吐温-80、聚乙二醇、聚氧乙烯蓖麻油、聚氧乙烯氢化蓖麻油、聚乙烯吡咯烷酮、泊洛沙姆(poloxamer)以及它们组成的混合体系。优选为吐温-80、聚乙二醇、聚氧乙烯蓖麻油、聚氧乙烯氢化蓖麻油或它们的混合体系。可通过常规实验确定表面活性剂的用量，以确保重建后得到澄清的溶液。有利地，尼莫地平与表面活性剂的重量比例约1∶30-1∶500，优选为1∶150-1∶300。
任选地，本发明药物组合物中还可加入药用冷冻干燥赋形剂。优选地，所述赋形剂选自甘露醇、山梨醇、氯化钠、葡萄糖、果糖、蔗糖、木糖醇、乳糖以及它们的混合物。优选为：甘露醇。尼莫地平与赋形剂的重量比为1∶100-1∶800，优选为1∶100-1∶300。
以组合物的总重量计，活性物质尼莫地平的用量约为0.5mg-50mg，优选为2mg-10mg。
本领域技术人员可根据临床制剂的需求和具体的生产设备，来调整冻干的周期。通常，可将均匀的制剂置于10至50ml的西林瓶中，预冻温度-20℃至-60℃，优选为-30℃至-40℃，预冻时间1小时至6小时，优选为3-4小时。冻干温度-10℃至-30℃，优选为-20℃至-25℃，冻干时间10小时至40小时，优选为20小时至25小时。冻干组合物的最终水分含量一般低于5％，优选为1％至2％。
本发明尼莫地平冻干组合物适于临床上应用。在使用前，可加入适量无菌药用水性稀释剂(例如，注射用水、生理盐水、葡萄糖水和其他已知的水性载体)，重建成供肌肉注射或静脉滴注(静脉内给药)用的胶体分散体或溶液制剂。
以下实施例旨在进一步说明本发明，并不对本发明的范围加以限制。
实施例1：制备含磷脂的粉针剂
取尼莫地平2mg、磷脂10mg和胆固醇2mg，加入无水乙醇5ml，搅拌至完全溶解，在旋转蒸发仪上进行减压干燥，除去溶剂，加入磷酸盐缓冲液5ml，搅拌至均匀，采用超声振荡，滤过，加入甘露醇100mg，置无菌西林瓶中，置冷冻干燥机内进行冷冻干燥，封口。即得浅黄色-淡黄色的尼莫地平粉针剂。
实施例2：制备含环糊精的粉针剂
取尼莫地平2mg，用2ml无水乙醇，搅拌至完全溶解，另取2-羟丙基-β-环糊精20mg，加7ml水溶解，搅拌下将尼莫地平溶液加入到2-羟丙基-β-环糊精的溶液中，制备成均匀的环糊精包合物。在旋转蒸发仪上进行减压干燥，挥去乙醇。在搅拌条件下，加入甘露醇300mg，溶液用事先经灭菌处理过的垂熔漏斗过滤，滤液置无菌西林瓶中，置冷冻干燥机内进行冷冻干燥，封口。即得浅黄色-淡黄色的尼莫地平粉针剂。
经X-射线衍射法确认，实施例2制得的药物组合物为包合物形式。
实施例3：制备含表面活性剂的粉针剂
取尼莫地平2mg、0.15g吐温-80、0.2g聚乙二醇-400、聚氧乙烯蓖麻油20mg和甘露醇0.3g，加水5ml，搅拌至完全溶解。用0.22μm的微孔滤膜过滤，置无菌西林瓶中，得微黄色澄清溶液，置冷冻干燥机内进行冷冻干燥，封口。即得浅黄色-淡黄色的尼莫地平粉针剂。
实验1：尼莫地平粉针剂的测定
含量的测定：UV-260紫外-可见分光光度计，选择358nm作为检测波长。
降解产物的测定：LC-10A高效液相色谱仪；C18(200×4.6mm，5μm)；乙腈-磷酸盐缓冲液(取磷酸2ml，加水1000ml)＝(70∶30)，流速为1.0ml/min，检测波长为238nm。结果表明，该色谱条件可将主药与各破坏(酸、碱、加热、光照、强氧化)产物分离。尼莫地平的最低检出限为0.5ng。
采用上述方法，对实施例3制得的尼莫地平粉针剂与常规小水针剂的稳定性进行考察，影响因素采用在4500LX照度的光照下放置10天，分别在第五天和第十天取样测定，考察数据如下表1。
表1
| 项目 | 样品 | 0天 | 5天 | 10天 |
| 外观及澄明度 | 粉针剂 | 淡黄色疏松快状，加水溶解后得微黄色澄清液体 | 淡黄色疏松快状，加水溶解后得微黄色澄清液体 | 淡黄色疏松快状，加水溶解后得微黄色澄清液体 |
| 水针剂 | 微黄色透明液体 | 微黄色透明液体 | 微黄色透明液体 | |
| 含量(％) | 粉针剂 | 97.5 | 96.4 | 94.6 |
| 水针剂 | 98.6 | 71.4 | 50.8 | |
| 降解产物(％) | 粉针剂 | 0.641 | 0.967 | 2.163 |
| 水针剂 | 1.030 | - | - |
以上结果表明：本发明粉针剂加水后可迅速重建得到澄清液体；在相同实验条件下，粉针剂的稳定性显著优于小水针剂。这种良好的溶解性和稳定性特性，不但保证了临床用药的安全性，也相应延长了尼莫地平的有效期。
动物试验表明，本发明尼莫地平粉针剂对血管无刺激性、无过敏反应。
尽管通过上述特定实施例对本发明作了描述，但是那些针对本发明所进行并不偏离本发明范畴的变化和改进，对于本领域技术人员是显而易见的。
Claims (8)
1.一种注射用冻干药物组合物，其中包括尼莫地平和选自磷脂、环糊精及其衍生物或表面活性剂的药用辅料，所述表面活性剂选自吐温-20、吐温-80、聚乙二醇、聚氧乙烯蓖麻油、聚氧乙烯氢化蓖麻油、聚乙烯吡咯烷酮、泊洛沙姆以及它们组成的混合体系，并且当药用辅料为磷脂时，所述组合物是脂质体或脂质复合物。
2.如权利要求1的组合物，其中磷脂选自：卵磷脂、大豆磷脂、脑磷脂、磷脂酸、二棕榈酸磷脂酰胆碱、氢磷脂酰乙醇氨、磷脂酰丝氨酸以及它们的混合物。
3.如权利要求1或2的组合物，其中尼莫地平与磷脂的重量比例1∶1-1∶100。
4.如权利要求1的组合物，其中环糊精及其衍生物选自β-环糊精、2-羟丙基-β-环糊精、3-羟丙基-β-环糊精、羟乙基-β-环糊精以及它们的混合物。
5.如权利要求1或4的组合物，其中尼莫地平和环糊精及其衍生物的比例1∶1至1∶20。
6.如权利要求1的组合物，其中表面活性剂选自吐温-20、吐温-80、聚乙二醇、聚氧乙烯蓖麻油、聚氧乙烯氢化蓖麻油、泊洛沙姆以及它们组成的混合体系。
7.如权利要求1或6的组合物，其中尼莫地平与表面活性剂的重量比例为1∶30-1∶500。
8.如权利要求1-7之一的组合物，还包括可药用冷冻干燥赋形剂，所述选自甘露醇、山梨醇、氯化钠、葡萄糖、果糖、蔗糖、木糖醇、乳糖以及它们的混合物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021556458A CN1165305C (zh) | 2002-12-13 | 2002-12-13 | 尼莫地平冻干组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021556458A CN1165305C (zh) | 2002-12-13 | 2002-12-13 | 尼莫地平冻干组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1424035A CN1424035A (zh) | 2003-06-18 |
| CN1165305C true CN1165305C (zh) | 2004-09-08 |
Family
ID=4752685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021556458A Expired - Lifetime CN1165305C (zh) | 2002-12-13 | 2002-12-13 | 尼莫地平冻干组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1165305C (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006500387A (ja) * | 2002-08-15 | 2006-01-05 | 雲清 劉 | 固形ナノ医薬およびその調製方法 |
| CN100393315C (zh) * | 2003-12-31 | 2008-06-11 | 山东瑞阳制药有限公司 | 一种新的尼莫地平组合物 |
| CN102266336A (zh) * | 2010-06-04 | 2011-12-07 | 张兆勇 | 一种盐酸贝尼地平制剂及其制备方法 |
| CN104706597B (zh) * | 2015-04-02 | 2018-04-03 | 天津中医药大学 | 一种用于鼻腔给药的尼莫地平脂质体及其制备方法 |
-
2002
- 2002-12-13 CN CNB021556458A patent/CN1165305C/zh not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1424035A (zh) | 2003-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1389089B1 (en) | Method and composition for solubilising a biologically active compound with low water solubility | |
| AU2016349408B2 (en) | Improved formulations of Levosimendan for intravenous administration as infusion or injection and of infusion concentrate | |
| RU2391966C1 (ru) | Наносистема на основе растительных фосфолипидов для включения биологически активных соединений и способ ее получения (варианты) | |
| KR20050105455A (ko) | 리포좀 제제의 제조 방법 | |
| CA2494157C (en) | Inclusion complexes of butylphthalide with cyclodextrin or its derivatives, a process for their preparation and the use thereof | |
| KR101468153B1 (ko) | 5α-안드로스테인-3β,5,6β-트리올 주사제 및 제조방법 | |
| AU2007246046A1 (en) | Pharmaceutical composition comprising high concentrate of polydatin | |
| CN1165305C (zh) | 尼莫地平冻干组合物 | |
| CN100525758C (zh) | 藤黄酸脂质体及其冻干粉针剂与制备方法 | |
| CN100428937C (zh) | 左西孟旦冷冻干燥组合物 | |
| CN100467024C (zh) | 氯诺昔康注射用组合物及其制备方法 | |
| JP7317804B2 (ja) | ドセタキセル結合体の医薬組成物及び調製方法 | |
| CN102309459A (zh) | 一种马尼地平冻干粉针的制备方法 | |
| WO2005072776A2 (en) | Liposomal formulations of the antineoplastic agents | |
| CN103025323B (zh) | 难溶性三环衍生物化合物的溶解度得到提高的药学组合物 | |
| CN1943585A (zh) | 灯盏花素前脂质体粉末制剂及其制备方法 | |
| CN101669916A (zh) | 一种硝苯地平冻干粉针的制备方法 | |
| EP3222273B1 (en) | Method for producing porous particle | |
| CN112999175B (zh) | 一种丁苯酞口服冻干粉及其制备方法和用途 | |
| UA75620C2 (en) | Stable pharmaceutical form of paclitaxel and method for the preparation thereof | |
| CN102058606A (zh) | 一种谷维素药物组合物 | |
| Gregory | Preparation of Liposomes and Oily Formulations by Freeze-Drying of Monophase Solutions | |
| CN115969781A (zh) | 一种枸橼酸爱地那非注射剂及其制备方法和用途 | |
| WO2018038687A1 (en) | Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex | |
| CN1589795A (zh) | 尼莫地平冻干组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: KUMIN LONGJIN MEDICINE CO., LTD. Free format text: FORMER OWNER: DONGFANG TIANXIANG MEDICAL TECHNOLOGY DEVELOPMENT CO., LTD., BEIJING Effective date: 20060512 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20060512 Address after: 650228, Yunnan Province, Kunming news Road, the next five piles Patentee after: Kunming Longjin Pharmaceutical Co.,Ltd. Address before: 100000 Beijing City Deshengmen West Street No. 15 ocean scenery apartment building 5 2 unit 702 room Patentee before: BEIJING DONGFANG TIANXIANG MED |
|
| C56 | Change in the name or address of the patentee |
Owner name: KUNMING LONGJIN PHARMACEUTICALS CO., LTD. Free format text: FORMER NAME: KUNMING LONGJIN PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 650228, Yunnan Province, Kunming news Road, the next five piles Patentee after: KUNMING LONGJIN PHARMACEUTICAL Co.,Ltd. Address before: 650228, Yunnan Province, Kunming news Road, the next five piles Patentee before: Kunming Longjin Pharmaceutical Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 650500 No. 789, Lanmao Road, majinpu sub district office, Kunming high tech Zone, Kunming, Yunnan Patentee after: KUNMING LONGJIN PHARMACEUTICAL Co.,Ltd. Address before: 650228, Yunnan Province, Kunming news Road, the next five piles Patentee before: KUNMING LONGJIN PHARMACEUTICAL Co.,Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20040908 |